USP22 and cancer: In addition, the in vitro proliferation assays further revealed that both A549-USP22−/− (Fig. 5e, left panel) and H1299-USP22−/− cancer cells (Fig. 5e, right panel) were more sensitive to 5 μM cisplatin than their parent cells over a period of 72 h of treatment.